APA

Wang W., Ma Y., Li J., Shi H., Wang L., Guo F., Zhang J., Li D., Mo B., Wen F., Liu T., Liu Y., Wang Y. & Wei Y. (20140422). Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. : Gene therapy.

Chicago

Wang W, Ma Y, Li J, Shi H-S, Wang L-Q, Guo F-C, Zhang J, Li D, Mo B-H, Wen F, Liu T, Liu Y-T, Wang Y-S and Wei Y-Q. 20140422. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. : Gene therapy.

Harvard

Wang W., Ma Y., Li J., Shi H., Wang L., Guo F., Zhang J., Li D., Mo B., Wen F., Liu T., Liu Y., Wang Y. and Wei Y. (20140422). Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. : Gene therapy.

MLA

Wang W, Ma Y, Li J, Shi H-S, Wang L-Q, Guo F-C, Zhang J, Li D, Mo B-H, Wen F, Liu T, Liu Y-T, Wang Y-S and Wei Y-Q. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. : Gene therapy. 20140422.